ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Clinical trials for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Donor immune cells take on Virus-Linked cancer after transplant
Disease control Recruiting nowThis phase 3 trial tests tabelecleucel, a cell therapy made from donor immune cells, in 115 organ or stem cell transplant patients who developed a rare cancer (EBV+ PTLD) after standard treatment failed. The goal is to see if it can shrink tumors and improve outcomes. Participant…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a lower drug dose prevent transplant complications just as well?
Disease control Recruiting nowThis study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after stem cell transplants from unrelated or half-matched donors. About 316 participants will receive either a reduced dose (35 mg/kg) or the standard dose (50 mg/kg),…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Phase: PHASE3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC